Sign in
Taking peopleNo phase

Studying nerve damage in the visual pathways of people with optic neuritis

Examines the eye's visual pathways to understand nerve damage in inflammatory brain diseases.

Key facts

Who runs it
University Hospital, Lille
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
VIsual Pathways Model in Neuro-inflammatory Disorders
Status
Recruiting
People taking part
100 people, planned
Started
7 Oct 2022
Expected to end
7 Apr 2028
Type of study
Observational
Treatments tested
  • Clinical examen
Record updated
20 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a recent episode of optic neuritis (inflammation of the nerve of the eye). It studies how nerve damage happens in inflammatory diseases of the brain and spinal cord.

Age
18 to 65 years
Sex
All sexes
Disease stage
Optic neuritis that started less than 4 weeks ago, confirmed by an eye and nerve specialist. People who already have an inflammatory disease of the brain or spinal cord can still join.

Main reasons for not taking part

  • Earlier optic neuritis in the same eye as the recent episode
  • Past retina disease, such as retinal detachment, glaucoma, retinopathy or retina surgery
  • Diabetes or long-term heavy alcohol use
  • Unable to have an MRI scan
  • Pregnant women, or people under guardianship

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • - Male or female
  • Aged between 18 and 65 years
  • Presenting a clinical picture of optic neuritis for less than 4 weeks, confirmed by neuro-ophthalmological assessment
  • Patient having given written consent to participate in the study
  • Patient with social insurance
  • Patient willing to comply with all study procedures and duration

Who cannot take part

  • - history of optic neuritis on the same side as the recent episode for which the patient is being treated
  • history of retinal pathology (retinal detachment, glaucoma, retinopathies, retinal surgery)
  • diabetes
  • administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent; A history of pre-existing CNS inflammatory demyelinating disease is not a criterion for non-inclusion
  • chronic alcohol intoxication
  • contraindications to MRI
  • pregnant women
  • persons under protective supervision (ex : guardianship)
  • minors
  • persons deprived of their liberty

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

In neuroinflammatory diseases of the central nervous system (CNS) such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and anti-MOG antibody-associated disorders (MOGAD), neuronal degeneration is the consequence of inflammatory and demyelinating lesions in the brain, optic nerve and spinal cord. Both white and grey matter are systematically affected. Lesions of the perivascular spaces containing cerebrospinal fluid (CSF) and meningeal inflammation seem to play an important role in the pathophysiology of these neuroinflammatory diseases. Currently, the interrelation of all these aspects is not clearly established in the pathophysiology of these diseases. In order to better understand the mechanisms that lead to and underlie the clinical disability of patients with these diseases, we need in vivo study models that allow the in-depth study of the neurodegenerative process and the identification of its causes. In this perspective, we make the hypothesis that the visual pathways model is very relevant to measure neuro-axonal loss and to explore the different mechanisms involved in neurodegeneration during MS and other CNS demyelinating diseases. Researchers have at their disposal many tools that allow them to analyse and quantify the neurodegenerative process in a reproducible and very precise manner from a structural and functional point of view, while taking into account possible vascular involvement (MRI, optical coherence tomography - angiography, etc…).

The group in the trial

  • optic neuritis patients

    Patients suffering from an acute episode of optic neuritis will be included. There will be only one group of patients prospectively followed-up.

    Treatment: Clinical examen

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study of the VIsual Pathways MODEL for a Better Understanding of Neurodegeneration in Inflammatory and Demyelinating Disorders of Central Nervous System
Plain-language title
Studying nerve damage in the visual pathways of people with optic neuritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT05487989, who can take part
Record updated
20 August 2025